SCHEMBL302099

SCHEMBL302099

COc1cc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2)ccc1C(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.54
GFER P55789 2/20 0.52
LMNA P02545 3/20 0.52
MEN1 O00255 1/20 0.52
HTT P42858 2/20 0.52
CNR1 P21554 1/20 0.52
CNR2 P34972 1/20 0.52
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TSHR P16473 2/20 0.49
HTR1A P08908 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR7 P34969 1/20 0.47
DRD3 P35462 1/20 0.47
HTR6 P50406 1/20 0.47
KDM4E B2RXH2 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274413 0.88 LMNA (0.56) KMT2ALMNAMEN1HTTCNR1
SCHEMBL302104 0.82 LMNA (0.61) KMT2ALMNAMEN1HTTCNR1
SCHEMBL1711049 0.82 LMNA (0.62) KMT2ALMNAMEN1HTTCNR1
SCHEMBL303551 0.82 LMNA (0.60) KMT2ALMNAMEN1HTTCNR1
SCHEMBL303307 0.81 LMNA (0.71) KMT2ALMNAMEN1HTTCNR2
SCHEMBL304091 0.79 LMNA (0.56) KMT2ALMNAMEN1HTTMAPT
SCHEMBL303907 0.77 LMNA (0.65) KMT2ALMNAHTTCNR2MAPT
SCHEMBL1711093 0.77 LMNA (0.71) KMT2ALMNAHTTCNR1CNR2
SCHEMBL302112 0.77 LMNA (0.65) KMT2ALMNAMEN1HTTCNR1
SCHEMBL1966437 0.76 HTR7 (0.69) KMT2ALMNAMEN1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 KMT2A 777/4885GFER 3672/4885LMNA 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.